Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurotech has initiated a phase II clinical trial of NT-501, the company's lead product for the treatment of visual loss associated with the dry form of age related macular degeneration.
Subscribe to our email newsletter
The phase II trial is a randomized dose ranging study that will evaluate the efficacy and safety of the CNTF implant and will be conducted at the National Eye Institute in Bethesda, Maryland.
NT-501 is an intraocular, polymer implant containing human retinal epithelial cells genetically modified to secrete ciliary neurotrophic factor (CNTF). The implant is designed to continuously release CNTF directly in the eye to the diseased retinal tissue for sustained periods of time.
“Dry AMD is a form of retinal disease that needs serious attention and we are very pleased to begin the phase II trial for the indication,” stated Ted Danse, CEO of Neurotech. “We believe the improvement in visual acuity observed in our phase I trial will translate into a similar benefit for patients with advanced stage dry AMD.”
An open-label phase I clinical trial of NT-501 was conducted in patients with retinitis pigmentosa (RP) at the National Eye Institute. The results confirmed that CNTF can be safely delivered into the vitreous of patients with RP, and some patients experienced improvement in their visual acuity score.